Ontology type: schema:ScholarlyArticle
2003-05
AUTHORSI. Vergote, J.F.R. Robertson, U. Kleeberg, G. Burton, C.K. Osborne, L. Mauriac
ABSTRACTPURPOSE: This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex'). PATIENTS AND METHODS: A combined total of 423 patients received fulvestrant 250 mg as a monthly intramuscular injection. After progression on fulvestrant, some patients received another endocrine therapy. Responses to subsequent endocrine therapy were assessed using a questionnaire sent to the trial investigators. Best responses were classified as a complete or partial response (CR or PR), stable disease (SD) lasting > or = 24 weeks, or disease progression. RESULTS: Follow-up data were available for 54 patients who derived clinical benefit (CB, defined as CR, PR or SD) from fulvestrant and who received subsequent endocrine therapy, resulting in a PR in 4 patients, SD in 21 patients, and disease progression in 29 patients. Data were available for 51 patients who derived no CB from fulvestrant and who received further endocrine therapy, resulting in a PR in 1 patient, SD in 17 patients, and disease progression in 33 patients. Aromatase inhibitors were used as subsequent endocrine therapy in > 80% of patients. CONCLUSIONS: After progression on fulvestrant, patients may retain sensitivity to other endocrine agents. Fulvestrant provides an additional option to existing endocrine therapies for the treatment of advanced or metastatic breast cancer in postmenopausal women, and may provide the opportunity to extend the sequence of endocrine regimens before cytotoxic chemotherapy is required. More... »
PAGES207-211
http://scigraph.springernature.com/pub.10.1023/a:1023983032625
DOIhttp://dx.doi.org/10.1023/a:1023983032625
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1001709392
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/12825855
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Androstenedione",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents, Hormonal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aromatase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Breast Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Progression",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Double-Blind Method",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Down-Regulation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Resistance, Neoplasm",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Enzyme Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Estradiol",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Estrogen Receptor Modulators",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Megestrol Acetate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Nitriles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Postmenopause",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Salvage Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Triazoles",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Universitaire Ziekenhuizen Leuven",
"id": "https://www.grid.ac/institutes/grid.410569.f",
"name": [
"University Hospitals, Leuven, Belgium"
],
"type": "Organization"
},
"familyName": "Vergote",
"givenName": "I.",
"id": "sg:person.0706143575.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706143575.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nottingham City Hospital",
"id": "https://www.grid.ac/institutes/grid.412920.c",
"name": [
"Nottingham City Hospital, Nottingham, UK"
],
"type": "Organization"
},
"familyName": "Robertson",
"givenName": "J.F.R.",
"id": "sg:person.07764637207.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Haematologische/Oncologische Praxis, Hamburg, Germany"
],
"type": "Organization"
},
"familyName": "Kleeberg",
"givenName": "U.",
"id": "sg:person.01324174537.45",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324174537.45"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Louisiana State University Health Sciences Center Shreveport",
"id": "https://www.grid.ac/institutes/grid.411417.6",
"name": [
"Louisiana State University Health Science Center, Shreveport, LA, USA"
],
"type": "Organization"
},
"familyName": "Burton",
"givenName": "G.",
"id": "sg:person.07760047337.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07760047337.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Houston Methodist",
"id": "https://www.grid.ac/institutes/grid.63368.38",
"name": [
"Breast Center at Baylor College of Medicine and Methodist Hospital, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Osborne",
"givenName": "C.K.",
"id": "sg:person.01117361752.88",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117361752.88"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institut Bergoni\u00e9",
"id": "https://www.grid.ac/institutes/grid.476460.7",
"name": [
"Bergonie Institute, Bordeaux, France"
],
"type": "Organization"
},
"familyName": "Mauriac",
"givenName": "L.",
"id": "sg:person.01271107205.26",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271107205.26"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/s0959-8049(01)00350-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005235495"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/(sici)1097-0142(19980701)83:1<1::aid-cncr1>3.0.co;2-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011845112"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1996.357",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012787769",
"https://doi.org/10.1038/bjc.1996.357"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1996.357",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012787769",
"https://doi.org/10.1038/bjc.1996.357"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0960-0760(01)00140-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016224520"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1023/a:1005828731462",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018344209",
"https://doi.org/10.1023/a:1005828731462"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1159/000055285",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1021121785"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00685924",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028594759",
"https://doi.org/10.1007/bf00685924"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00685924",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028594759",
"https://doi.org/10.1007/bf00685924"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1023/a:1006391902868",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037141890",
"https://doi.org/10.1023/a:1006391902868"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00662401",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044518496",
"https://doi.org/10.1007/bf00662401"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00662401",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044518496",
"https://doi.org/10.1007/bf00662401"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(95)91156-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047740754"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(95)91156-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047740754"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0959-8049(02)80309-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1054666367"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jnci/87.10.746",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1059819285"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2002.10.057",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064203147"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2002.10.058",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064203148"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2000.18.22.3758",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1074728220"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2001.19.10.2596",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1074814003"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1074881954",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1077661065",
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.1996.14.7.2000",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1082907367"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.1998.16.2.453",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083213024"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1083239805",
"type": "CreativeWork"
}
],
"datePublished": "2003-05",
"datePublishedReg": "2003-05-01",
"description": "PURPOSE: This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex').\nPATIENTS AND METHODS: A combined total of 423 patients received fulvestrant 250 mg as a monthly intramuscular injection. After progression on fulvestrant, some patients received another endocrine therapy. Responses to subsequent endocrine therapy were assessed using a questionnaire sent to the trial investigators. Best responses were classified as a complete or partial response (CR or PR), stable disease (SD) lasting > or = 24 weeks, or disease progression.\nRESULTS: Follow-up data were available for 54 patients who derived clinical benefit (CB, defined as CR, PR or SD) from fulvestrant and who received subsequent endocrine therapy, resulting in a PR in 4 patients, SD in 21 patients, and disease progression in 29 patients. Data were available for 51 patients who derived no CB from fulvestrant and who received further endocrine therapy, resulting in a PR in 1 patient, SD in 17 patients, and disease progression in 33 patients. Aromatase inhibitors were used as subsequent endocrine therapy in > 80% of patients.\nCONCLUSIONS: After progression on fulvestrant, patients may retain sensitivity to other endocrine agents. Fulvestrant provides an additional option to existing endocrine therapies for the treatment of advanced or metastatic breast cancer in postmenopausal women, and may provide the opportunity to extend the sequence of endocrine regimens before cytotoxic chemotherapy is required.",
"genre": "research_article",
"id": "sg:pub.10.1023/a:1023983032625",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1092777",
"issn": [
"0167-6806",
"1573-7217"
],
"name": "Breast Cancer Research and Treatment",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "79"
}
],
"name": "Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy",
"pagination": "207-211",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"082435e4f60ab6666305e03723d31a4ae196dc9d7d5ffa0d4eb63c7130cfb8c7"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"12825855"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"8111104"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1023/a:1023983032625"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1001709392"
]
}
],
"sameAs": [
"https://doi.org/10.1023/a:1023983032625",
"https://app.dimensions.ai/details/publication/pub.1001709392"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T16:40",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000502.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1023%2FA%3A1023983032625"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1023983032625'
This table displays all metadata directly associated to this object as RDF triples.
283 TRIPLES
21 PREDICATES
75 URIs
46 LITERALS
34 BLANK NODES